Medicare Enrolled
Dr. Andrew Dold, D.O.
Infectious Disease · Dacula, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Dold from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dold?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Dold
Dr. Andrew Dold is an infectious disease specialist in Dacula, GA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Dold performed 9,329 Medicare services across 997 unique beneficiaries.
Between the years covered by Open Payments, Dr. Dold received a total of $1,009,632 from 44 pharmaceutical and/or device companies across 2473 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in infectious disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Dold is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 8% volume in GA
$1,009,632 industry payments
Medicare Practice Summary
Medicare Utilization ↗9,329
Medicare services
Top 8% in GA for infectious disease
997
Unique beneficiaries
$35
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~491 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Oritavancin antibiotic injection, 10 mg This procedure involves the administration of a 10 mg dose of oritavancin, an antibiotic medication, via injection. |
6,960 | $32 | $110 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
459 | $83 | $310 |
| Injection, amikacin sulfate, 100 mg | 409 | $1 | $45 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
194 | $60 | $205 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
184 | $0 | $15 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
155 | $16 | $340 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
144 | $49 | $265 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
139 | $8 | $45 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
119 | $1 | $15 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
85 | $132 | $780 |
| Ertapenem sodium injection, 500 mg An injection of ertapenem sodium, an antibiotic medication, administered at a dose of 500 mg. |
82 | $10 | $144 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
78 | $11 | $98 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
72 | $71 | $220 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
63 | $99 | $471 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
48 | $49 | $220 |
| New patient office visit, complex (60-74 min) | 36 | $172 | $635 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
23 | $91 | $372 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
18 | $99 | $482 |
| Pneumonia vaccine administration This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider. |
18 | $31 | $98 |
| Pneumococcal conjugate vaccine (PCV20) An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria. |
17 | $281 | $703 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
15 | $153 | $839 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
11 | $38 | $206 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.5% high complexity
82.7% medium
12.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,009,632
Total received (2018-2024)
Avg $144,233/year across 7 years
Top 0% in GA for infectious disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
44
Companies
2,473
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$862,761 (85.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$137,919 (13.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,952 (0.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$230,482
2023
$292,694
2022
$146,893
2021
$98,880
2020
$56,309
2019
$115,564
2018
$68,809
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Paratek Pharmaceuticals, Inc.
$155,392
ViiV Healthcare Company
$36,737
Gilead Sciences, Inc.
$12,198
Ferring Pharmaceuticals Inc.
$6,973
Insmed, Inc.
$6,787
Melinta Therapeutics, LLC
$5,852
Cumberland Pharmaceuticals, Inc.
$4,050
PFIZER INC.
$1,685
Merck Sharp & Dohme LLC
$208
ABBVIE INC.
$137
Grifols USA, LLC
$97
Astellas Pharma US Inc
$94
Takeda Pharmaceuticals U.S.A., Inc.
$76
ADMA BioManufacturing LLC
$72
Shionogi Inc
$57
La Jolla Pharmaceutical Company
$47
Theratechnologies Inc.
$21
Top 3 companies account for 88.7% of 2024 payments
All-time payments by company (2018-2024) ›
Paratek Pharmaceuticals, Inc.
$433,595
Insmed, Inc.
$162,475
ViiV Healthcare Company
$117,050
Melinta Therapeutics, LLC
$73,318
Merck Sharp & Dohme Corporation
$44,088
Melinta Therapeutics, Inc.
$31,633
Astellas Pharma US Inc
$31,355
Allergan Inc.
$28,603
Gilead Sciences, Inc.
$27,910
Ferring Pharmaceuticals Inc.
$19,714
TETRAPHASE PHARMACEUTICALS, INC.
$9,706
Shionogi Inc
$9,569
Allergan, Inc.
$5,202
Cumberland Pharmaceuticals, Inc.
$4,266
PFIZER INC.
$3,212
Janssen Biotech, Inc.
$1,254
CIPLA USA INC.
$1,173
Regeneron Healthcare Solutions, Inc.
$1,013
Takeda Pharmaceuticals U.S.A., Inc.
$903
Merck Sharp & Dohme LLC
$567
Theratechnologies Inc.
$377
La Jolla Pharmaceutical Company
$348
Grifols USA, LLC
$325
Octapharma USA, Inc.
$296
ABBVIE INC.
$228
Janssen Products, LP
$214
AbbVie Inc.
$213
CSL Behring
$169
Nabriva Therapeutics, plc
$150
EMD Serono, Inc.
$113
ADMA BioManufacturing LLC
$101
Shire North American Group Inc
$98
AIMMUNE THERAPEUTICS, INC.
$83
MAYNE PHARMA INC.
$70
AngioDynamics, Inc.
$48
Janssen Pharmaceuticals, Inc
$39
Horizon Therapeutics plc
$34
Janssen Scientific Affairs, LLC
$21
GRT US Holding, Inc.
$19
Vyera Pharmaceuticals, LLC
$18
Theravance Biopharma, Inc.
$17
PORTOLA PHARMACEUTICALS, INC.
$17
The Medicines Company
$16
AbbVie, Inc.
$13
Top 3 companies account for 70.6% of all-time payments
Associated products mentioned in payments ›
APRETUDE · AVYCAZ · Arikayce · BEVYXXA · Baxdela · Biktarvy · CABENUVA · CHANTIX · CRESEMBA · CUBICIN RF · CUTAQUIG · CUVITRU · Cresemba · DALVANCE · DELSTRIGO · DIFICID · DORYX · DOVATO · Daraprim Tablet 25mg · EGRIFTA · EGRIFTA SV · ELIQUIS · Fetroja · GATTEX · Gamunex-C · HYQVIA · Hizentra · ISENTRESS · JULUCA · KRYSTEXXA · Kimyrsa · MAVYRET · Mavyret · NOXAFIL · NUZYRA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ORBACTIV · Orbactiv · PANZYGA · PIFELTRO · PIPELINE · PNEUMOVAX 23 · PREVNAR - 13 · PREVNAR 13 · PREVNAR 20 · PREZCOBIX · PREZISTA · Qutenza · REBYOTA · RUKOBIA · Rezzayo · SEROSTIM · SIVEXTRO · SYMTUZA · Serostim · Sivextro · Sunlenca · Symtuza · TEFLARO · TRIUMEQ · TROGARZO · VIBATIV · VOWST · Vabomere · XERAVA · Xembify · Xenleta · Xerava · ZEMDRI (PLAZOMICIN) · ZERBAXA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (86%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in infectious disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for infectious disease in GA.
Geographic Context
Infectious diseases within 10 mi
36
Per 100K population
3.7
County median income
$84,823
Nearest hospital
NORTHSIDE HOSPITAL GWINNETT
3.7 mi
3.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Dold is a mixed practice specialist, with above-average Medicare volume (top 8% in GA), with speaking/promotional industry engagement in the top 0% of GA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Dold experienced with oritavancin antibiotic injection, 10 mg?
Based on Medicare claims data, Dr. Dold performed 6,960 oritavancin antibiotic injection, 10 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Dold receive payments from pharmaceutical companies?
Yes. Dr. Dold received a total of $1,009,632 from 44 companies across 2,473 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dold's costs compare to other infectious diseases in Dacula?
Dr. Dold's average Medicare payment per service is $35. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dold) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Infectious Diseases in Dacula
Browse infectious diseases in Dacula ranked by procedure volume and transparency data.
Highest volume
Top Infectious Diseases in GA
Infectious diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Infectious Diseases in GA
Which GA infectious diseases receive the most from drug and device companies.
By company
Paratek Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Paratek Pharmaceuticals, Inc.
By company
Insmed, Inc. Payments to Doctors
See all physicians who received payments from Insmed, Inc.
By company
ViiV Healthcare Company Payments to Doctors
See all physicians who received payments from ViiV Healthcare Company.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology